Document Type
Article
Publication Date
12-12-2022
Abstract
The treatment landscape for acute myeloid leukemia (AML) has changed substantially in recent years. The introduction of newer therapies, including oral agents, less myelosuppressive agents, and parenteral regimens suitable for outpatient administration, has made it feasible for select patients to receive therapy in the outpatient setting and in community practices. Thorough patient evaluation (including molecular testing), planned supportive care (eg, transfusion support, antimicrobial prophylaxis), and vigilant patient monitoring (for tumor lysis syndrome and adverse events) by a multidisciplinary team are required for successful management of patients both in the community and at specialized leukemia centers. Some patients are unable or unwilling to travel to larger academic centers for treatment, and treatment of AML in the community setting may have potential advantages compared to less conveniently located academic/leukemia centers. This includes reduction of financial hardship for patients and their families and often better opportunities for family/caregiver support. Additionally, partnership between community practices and academic/leukemia centers is often crucial to optimizing AML management for many patients, as collaboration may facilitate access to additional expertise and trials, multidisciplinary teams for supportive care, easier transition to hematopoietic cell transplantation, and access to sophisticated molecular testing. In this review, we discuss AML treatment and management in the community setting, available therapies, and circumstances in which a referral to and co-management with an academic/leukemia center is more strongly recommended.
Recommended Citation
Benton, Christopher; Grunwald, Michael R; Safah, Hana; and Kasner, Margaret, "Co-management Strategies for Acute Myeloid Leukemia Patients in the Community Setting" (2022). Department of Medical Oncology Faculty Papers. Paper 221.
https://jdc.jefferson.edu/medoncfp/221
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
PubMed ID
36578924
Language
English
Comments
This article is the author's final published version in Frontiers in Oncology, Volume 12, December 2022, Article number 1060912.
The published version is available at https://doi.org/10.3389/fonc.2022.1060912.
Copyright © 2022 Benton, Grunwald, Safah and Kasner
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.